Publications by authors named "Ju-Yeon An"
Ecotoxicol Environ Saf
November 2024
Article Synopsis
- * This study introduced a new method using a respirometer to measure oxygen consumption in ICR mice exposed to various concentrations of benzene, toluene, and xylene, revealing significant decreases in respiration rates at high concentrations of benzene and toluene.
- * The method was validated in a model of pulmonary fibrosis, showing a strong link between weight loss and decreased oxygen consumption, suggesting oxygen consumption might serve as a reliable endpoint in inhalation toxicity assessments without needing to sacrifice animals.
Int Immunopharmacol
October 2024
Article Synopsis
- The skin serves as a protective barrier against external irritants, and Pilea mongolica (P. mongolica) is a traditional Chinese herb that may help reduce inflammation, despite limited research on its effects.
- This study investigated the anti-inflammatory properties of the methanol extract of P. mongolica (MEPM) on LPS-stimulated human skin cells, showing that it significantly lowered inflammatory markers without being toxic to the cells.
- The study identified geraniin, an active compound in MEPM, as a key player in these anti-inflammatory effects, suggesting that MEPM and geraniin could be valuable for developing natural cosmetic products.
Ecotoxicol Environ Saf
May 2024
Article Synopsis
- Particulate matter (PM) pollution, linked to various health issues, has not been thoroughly studied in relation to the development of schizophrenia.
- This study exposed preadolescent mice to PM and examined the impact on schizophrenia-like behaviors, finding that PM exposure worsened symptoms like social deficits and cognitive impairments in adulthood.
- The research also revealed that PM exposure reduced levels of brain-derived neurotrophic factor (BDNF) and affected related signaling pathways, suggesting a biological mechanism behind the exacerbation of schizophrenia symptoms.
Pharmaceutics
December 2023
Article Synopsis
- * A study tested the effects of a novel herbal complex called LK5, which has anti-inflammatory properties, on HaCaT cells and in a mouse model of AD.
- * Results showed that LK5 reduced expression of inflammatory cytokines, improved clinical symptoms in mice, and inhibited itch, indicating its potential to modulate the immune response and alleviate AD symptoms by targeting the JAK-STAT pathway.
Article Synopsis
- The NLRP3 inflammasome, which is promoted by certain agents, plays a key role in increasing IL-1β levels, contributing to the worsening of atopic dermatitis (AD) symptoms.
- Despite its critical role, there are currently no drugs specifically targeting the NLRP3 inflammasome for AD patients.
- Research showed that MAEO can inhibit NLRP3 inflammasome activation and reduce AD symptoms in laboratory tests and animal models, suggesting its potential as a treatment for AD.
J Ethnopharmacol
October 2023
Article Synopsis
- Cynanchum paniculatum has a history of use in East Asia for its pain-relieving and antiviral properties, and traditional texts indicate potential benefits for treating psychotic symptoms like hallucinations and delusions.
- The study investigated the effects of C. paniculatum and its main compound, paeonol, on mice with schizophrenia-like behaviors induced by MK-801, finding that paeonol may help alleviate symptoms.
- Results showed that both C. paniculatum extract and paeonol improved sensorimotor gating and cognitive deficits in the mice, suggesting paeonol could be a promising treatment for schizophrenia-related issues.
Pharmaceuticals (Basel)
September 2022
Article Synopsis
- Atopic dermatitis (AD) is a long-lasting skin condition that mainly affects kids and teens, resulting in itching, dry skin, and redness, but it can also start in adults.
- Current treatments like corticosteroids can have side effects including weight loss and acne.
- The study found that a specific treatment inhibited inflammation in skin cells and improved symptoms in mice with AD-like skin issues, highlighting its potential benefits for managing the condition by targeting the NLRP3 inflammasome pathway.
